1 Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer research. 1990;50:3605–9.
2 Chandran R, Gardiner SK, Smith SD, et al. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. British journal of haematology. 2013;163:407–9.
3 Monnereau A, Slager SL, Hughes AM, et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs. 2014;2014:115–24.
4 Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–30.
5 Cunha BA, Munoz-Gomez S, Gran A, et al. Persistent Legionnaire’s disease in an adult with hairy cell leukemia successfully treated with prolonged levofloxacin therapy. Heart & lung: the journal of critical care. 2015;44:360–2.
6 Dasanu CA, Van den Bergh M, Pepito D, et al. Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought? Current medical research and opinion. 2015;31:17–23.
7 Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia & lymphoma. 1994;14 Suppl 1:57–61.
8 Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. The New England journal of medicine. 2011;364:2305–15.
9 Sherman MJ, Hanson CA, Hoyer JD. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. American journal of clinical pathology. 2011;136:390–9.
10 Uppal G, Ly V, Wang ZX, et al. The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. American journal of clinical pathology. 2015;143:120–5.
11 Poret N, Fu Q, Guihard S, et al. CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer research. 2015;75:3902–11.
12 Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114:4696–702.
13 Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330–2.
14 Golomb HM. Hairy cell leukemia: lessons learned in twenty-five years. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1983;1:652–6.
15 Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60.
16 Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leukemia & lymphoma. 2011;52 Suppl 2:21–24.
17 Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. The New England journal of medicine. 1990;322:1117–21.
18 Naik RR, Saven A. My treatment approach to hairy cell leukemia. Mayo Clinic proceedings. 2012;87:67–76.
19 Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2’-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 1995;1:385–90.
20 Von Rohr A, Schmitz SF, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology: official journal of the European Society for Medical Oncology. 2002;13:1641–9.
21 Zenhausern R, Schmitz SF, Solenthaler M, et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leukemia & lymphoma. 2009;50:1501–11.
22 Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leukemia & lymphoma. 1999;35:555–65.
23 Legrand O, Vekhoff A, Marie JP, et al. Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects. British journal of haematology. 1997;99:165–7.
24 Bennett C, Vardiman J, Golomb H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. The American journal of medicine. 1986;80:891–6.
25 Saven A, Burian C, Adusumalli J, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999;93:2471–7.
26 Goldschmidt N, Ganzel C, Attias D, et al. Pegfilgrastim prophylaxis for cladribine-induced neutropenia in patients with hairy-cell leukemia. Acta haematologica. 2014;132:118–21.
27 Orlando R, Tosone G, Tiseo D, et al. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients? Infection. 2006;34:282–4.
28 Zulian GB, Roux E, Tiercy JM, et al. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. British journal of haematology. 1995;89:83–9.
29 Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21:891–6.
30 Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–81.
31 Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Archives of pathology & laboratory medicine. 2006;130:374–7.
32 Rosenberg JD, Burian C, Waalen J, et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 2014;123:177-183.
33 Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leukemia & lymphoma. 2009;50 Suppl 1:12–17.
34 Dasanu CA, Alexandrescu DT. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert opinion on pharmacotherapy. 2010;11:41–50.
35 Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. Journal of the National Cancer Institute. 2007;99:215–222.
36 Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1995;13:974–82.
37 Damasio EE, Clavio M, Masoudi B, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. European journal of haematology. 2000;64:47–52.
38 Benz R, Siciliano RD, Stussi G, et al. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. European journal of haematology. 2009;82:194–200.
39 Ramakrishna R, Manoharan A. Sustained long-term remissions with weekly interferon maintenance therapy in hairy cell leukemia. Asia-Pacific journal of clinical oncology. 2010;6:210–2.
40 M. Angelopoulou KA, Sachanas S, Kokoris S, TP. Vassilakopoulos ZG, MN. Dimopoulou, FN. Kontopidou, E. Plata PT, Dimitriadou E, MP. Siakantaris MP, Pangalis GA. Long term follow up of hairy cell leukemia patients treated with interferon-a. The importance od maintenance. Abstract 0117. Haematologica 2007.
41 Zenhausern R, Simcock M, Gratwohl A, et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica 2008;93:1426–8.
42. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110:2240-2247.
43 Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19:6313–21.
44 Dietrich S, Pircher A, Endris V, et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016;127:2847–55.
45 Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. American journal of hematology. 2017;92:1382–90.